Introduction
Kidney transplantation is the preferred modality of renal replacement therapy for many patients with end-stage renal disease (ESRD) 1 . Compared to remaining on transplant waiting list, kidney transplantation improves long-term survival 2 , enhances quality of life 3 , demonstrates cost benefit 4 , and rectifies uraemia and metabolic abnormalities contributing to overall sense of well-being 5 . Despite several advantages following successful transplantation, the corollary of the current shortage of organs is that only a proportion of patients on transplant waiting list proceed to transplantation, with up to 40% dying whilst waiting on dialysis 6 . It is crucial that the best possible use is made of those transplanted kidney (graft), and therefore optimising patient-and graft-survival following transplantation should be a priority in this patient group.
Post print, cite as: Chan, W., Bosch, J.A., Jones, D., McTernan, P.G., Phillips, A.C., & Borrows, R. (2014) . Obesity in kidney transplantation. Journal of Renal Nutrition, 24, 1-12. IF 1.57. http://dx.doi.org/10.1053/j.jrn.2013.09.002 Short-term patient-and graft-survival have substantially improved over the recent decades, with most centres reporting both survival rates at 1 year of greater than 90% 7 . However, long-term success has been difficult to accomplish as evident by the marginal increase in patient-and graft-survival rates over the past 15 years 8 . This phenomenon is multifactorial.
Firstly, modification of alloimmunity using immunosuppression has reduced short-term early acute rejection rates 8 , but the nephrotoxicity of immunosuppressive medication is known to limit long-term graft survival 9 . Secondly, the use of maintenance immunosuppressive therapy is associated with increased risk of infection and malignancy 10 . Thirdly, cardiovascular disease (CVD) is a well-known long-term complication in kidney transplant recipients (KTRs) 11 . It is both the leading cause of death following transplantation 12 and death with a functioning graft 13 .
According to the World Health Organization, overweight is defined as a BMI of 25.0 to 29.9 kg/m 2 ; and obesity is defined as a BMI of ≥ 30.0 kg/m 2 14 . Prior to transplantation, the role of obesity on long-term patient-and graft survival remains uncertain. However, available evidence suggests that obesity predisposes to delayed graft function with subsequent impact on graft failure 7 . Following transplantation, obesity is strongly associated with reduced long-term patient-and graft survival 7 , but it failed to display an independent relationship with CVD risk 15-18 . However, obesity leads to higher prevalence of CVD risk factors including hypertension, dyslipidaemia, diabetes mellitus and insulin resistance, all of which are independently associated with increased risk of graft failure 15-18 . These individual diseases also cluster as part of metabolic syndrome. A recent sub-analysis of the ALERT (Assessment of LEscol in Renal Transplantation) study revealed that metabolic syndrome was associated with increased risk of graft failure 19 . Obesity is modifiable by nutritional Post print, cite as: Chan, W., Bosch, J.A., Jones, D., McTernan, P.G., Phillips, A.C., & Borrows, R. (2014). Obesity in kidney transplantation. Journal of Renal Nutrition, 24, 1-12. IF 1.57. http://dx.doi.org/10.1053/j.jrn.2013.09.002 intervention, but the impact of weight loss resulting from these interventions on long-term patient-and graft-survival has not been well-established.
The purposes of this article were to review the relevant literature assessing the role of preand post-transplant obesity on patient-and graft-survival, to discuss the potential underlying mechanisms by which obesity induces its detrimental effects leading to inferior kidney transplant outcomes, and to explore the role of nutritional intervention on improving longterm outcomes of kidney transplantation. Finally, this article aims to identify gaps in current literature and recommends potential areas for future research.
Prevalence and impact of obesity prior to transplantation
Overweight and obesity are common at the time of transplantation 20 . Currently, 60% of KTRs are overweight at the time of transplantation, representing a 116% increase from 1987 20 . Indeed, many transplant centres in the UK and US exclude patients with a BMI greater than 30 or 35 kg/m 2 21 . A BMI ≥ 35 kg/m 2 was the third most common reason to exclude as many as 10% of patients from transplantation 22 . Despite this, the effect of pre-transplant obesity on patient-and graft-survival remains controversial, with several conflicting studies in the literature. Table 1 summarises the studies examining the impact of pre-transplant obesity on kidney transplant outcomes. In some studies, while pre-transplant obesity had no effect on long-term outcomes, it demonstrated a negative impact upon short-term outcomes including graft failure within the first year post-transplant 23 , post-transplant surgical complications and delayed graft function [24] [25] [26] [27] [28] [29] . Despite the lack of relationship between pre-Post print, cite as: Chan, W., Bosch, J.A., Jones, D., McTernan, P.G., Phillips, A.C., & Borrows, R. (2014). Obesity in kidney transplantation. Journal of Renal Nutrition, 24, 1-12. IF 1.57. http://dx.doi.org/10.1053/j.jrn.2013.09.002 transplant obesity and long-term outcomes in these studies, it is important to note that delayed graft function is associated with reduced long-term graft survival 7,30 . Some studies showed that obesity exerts a negative impact on long-term patient-and graft survival 7,31-36 .
In contrast, adverse impact of obesity on both short-and long-term outcomes were seen in some studies 31, 33 . Also, a study by Yamamoto et al 35 otherwise demonstrated that while obesity had no effect on short-term graft survival, decreased medium-and long-term graft survival were observed in obese KTRs. Finally, Streja et al showed that obesity was associated with graft loss, but had no effect on mortality 36 . In summary, studies with short- 
Impact of body composition prior to transplantation
Given the conflicting data on the effect of pre-transplant obesity on patient-and graftsurvival, a recent study explored the effect of body composition on long-term patient-and graft-survival rates. It showed that sarcopenic obesity prior to transplantation was associated with increased mortality and graft failure 36 , while sarcopenia in the study was defined as 
Impact of weight loss during transplant listing
Whilst the effect of pre-transplant obesity on patient-and graft-survival remains unclear, Schold et al reported that weight loss during transplant listing had no effect on long term outcomes following transplantation including mortality risk and graft loss across the entire BMI spectrum 37 . The same study also highlighted that substantial weight loss pre-transplant was associated with rapid weight gain following transplantation 37 . This finding, together with the observed "obesity paradox" in the dialysis population 38 , suggest that weight loss prior to transplantation may not necessarily be beneficial, as mortality risk during transplant listing and following transplantation is not alleviated. However, the authors highlighted that these information needs to be interpreted with caution as data on BMI was taken from the registry and crucial information including the nature of weight change and other aspects of nutritional status is therefore unavailable 37 . Intentional weight loss that is potentially beneficial may be masked by weight loss that is a manifestation of malnutrition or progressive disease 37 .
In addition, a retrospective study of the United States Renal Data System (USRDS) registry found that substantial weight loss was achieved with bariatric surgery in a cohort of patients prior to transplant-listing and wait-listed for transplantation 39 . These results were similar to findings from recent studies, which demonstrated that laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy were effective procedures for weight loss and improved candidacy for kidney transplantation 40,41 . However, perioperative complications and mortality within a 30-day period post bariatric surgery were evident 39,41 . Also, the impact of Post print, cite as: Chan, W., Bosch, J.A., Jones, D., McTernan, P.G., Phillips, A.C., & Borrows, R. (2014). Obesity in kidney transplantation. Journal of Renal Nutrition, 24, 1-12. IF 1.57. http://dx.doi.org/10.1053/j.jrn.2013.09.002 intentional weight loss induced by bariatric surgery on short-and long-term patient-and graft-survival has not yet been examined.
Prevalence and causes of obesity following transplantation
Weight gain following transplantation is very common and occurs in up to 50% of KTRs 42,43 , affecting both obese and non-obese patients 44 . The average weight gain following transplantation is between 10% and 35% of body weight, with the majority of weight gain within the first 12 months following transplantation 42,45-47 . Much of the weight gain posttransplant is attributed to an increase in body fat mass, especially in the abdominal area 48,49 .
Excessive weight gain and increased fat mass in KTRs is traditionally attributed to the immunosuppression treatment protocol post-transplantation. This is due to the well-known hyperphagic effect of steroids, and its adverse influence on adipocytes, resting energy expenditure and lipid oxidation, resulting in centripetal obesity i.e. increased fat deposition in the peritoneum, mediastinum, subcutaneous sites such as face and neck 49 . However, recent evidence suggests that the effect of steroids on weight gain is controversial. Table 2 summarises the studies showing the impact of steroids on weight gain and body composition. A recent study by Hoogeveen et al 7 showed that one year following transplant, BMI and BMI increments were both significant risk factors for mortality and graft failure in the longterm. In contrast, Kovesdy et al 56 reported that higher BMI was associated with lower mortality after adjustment for waist circumference, whereas higher waist circumference was associated with higher mortality after adjustment for BMI. The opposite association displayed by BMI and waist circumference highlighted the uncertainty of relying on BMI as a marker of obesity in view of its incapability to distinguish between visceral adiposity, subcutaneous adiposity and muscle mass. Additionally, clinically obese patients with exclusive subcutaneous fat excess were found in a normal metabolic state and demonstrated a limited deposition of fat at visceral sites 57 , conferring to reduced metabolic risk. These findings suggest that not only waist circumference appears to be a better prognostic marker for obesity than BMI, visceral adiposity adversely affect kidney transplant outcomes, and increased subcutaneous fat and/or muscle mass may be protective against mortality risk. In addition, recent data from a renal transplant population showed that lower urinary creatinine excretion, a proxy for reduced muscle mass, was associated with increased mortality and graft failure 58 .
Impact of obesity following transplantation

Obesity-related mechanisms of inferior kidney transplant outcomes
A number of mechanisms associating obesity and inferior transplant outcomes have been proposed, these are summarised in reduced muscle mass coupled with increased fat mass, appears to be the driving force behind these mechanisms.
A link between muscle mass and survival has been suggested, increased muscle mass has been proposed to improve skeletal, respiratory and cardiac muscle function, and consequently improve muscle-based oxidative mechanism leading to increased antioxidant defence 56 . Reduced muscle mass may therefore exerts a negative effect on the proposed mechanism, leading to increased risk of cardiovascular disease, cancer, neurodegenerative disorders, and other chronic conditions 59 . Also, gelsolin produced by the skeletal muscle has been shown to be associated with improved survival in dialysis patients 56 . Although the effect of gelsolin has not been studied in kidney transplantation, the depletion of which may explain the higher mortality risk in KTRs.
Negative metabolic effects of raised BMI and adiposity, particularly visceral adiposity, may explain the increased CVD risk and graft failure observed in KTRs. First of all, the ALERT trial showed that raised BMI was associated with inflammation 60 , where inflammatory markers including interleukin-6 (IL-6) and high-sensitivity c-reactive protein (hsCRP) were independently and positively associated with major cardiovascular events and all-cause mortality in KTRs 60 . Specifically, visceral adipose tissue is the most metabolically active obesity-related glomerulopathy, suggesting that these are important pathways leading to graft failure 7 . The lack of success could be explained by the nature of this study where no dietary advice was given during the program. At the first visit, patients were only given an evaluation of dietary intake followed by anthropometry assessment and a short description of the negative effects of obesity on post-transplant morbidity. Six months later at the second visit, patients then received dietary advice based on the analysis of the first visit.
Obesity intervention strategies
Lifestyle modification and behavioural intervention
In addition to dietetic intervention, increased physical activity level is an important lifestyle modification strategy for weight reduction. Zelle et al 75 reported an association between increased physical activity level and reduced mortality in KTRs independent of waist circumference, muscle mass, triglyceride and insulin levels. Table 3 . Importantly, both studies 52,76 using steroid minimisation Post print, cite as: Chan, W., Bosch, J.A., Jones, D., McTernan, P.G., Phillips, A.C., & Borrows, R. (2014). Obesity in kidney transplantation. Journal of Renal Nutrition, 24, 1-12. IF 1.57. http://dx.doi.org/10.1053/j.jrn.2013.09.002 have shown an increase in acute transplant rejection, which raises concerns over the use of steroid minimisation as a strategy for weight management.
Nutritional intervention vs pharmacological approach
Alternative strategies to weight management
Generally, weight management has proven to be a difficult challenge, involving calorie reduction, increased physical activity, and behavioural modification. Increasingly, pharmacological and surgical options are pursued to tackle the problem. The use of antiobesity medications has not been exclusively studied in KTRs. Sibutramine was associated with hypertension 77 , Orlistat interfered with cyclosporine absorption decreasing its bioavailability 78 , and Rimonabant treatment led to increased systemic exposure of Cyclosporin A as well as psychiatric complications in some patients 79 . Bariatric surgery yielded substantial weight loss in KTRs 39 , and gastric bypass procedure has shown promise in selected KTRs, leading to reduction in cardiovascular co-morbidity 80 .
Future research on obesity in kidney transplantation
Currently, the effect of pre-transplant obesity on patient-and graft-survival remains unclear. At present, there is a lack of pre-clinical data on this topic, thereby highlighting the need to develop experimental animal models of renal transplant with obesity in parallel to ongoing clinical studies. This will not only aid in dissecting the pathophysiology of obesity in renal transplants, but also paving the way for possible interventional studies in the future. In addition, further clinical research should assess the effect of varying adipokines on inflammation and the associated effects on graft failure and mortality. Similarly, the role of muscle mass in KTRs on long-term transplant outcomes has not been well-investigated.
Conclusion
In summary, obesity is common both at the time of transplantation and following transplantation. While the implication of pre-transplant obesity on kidney transplant outcomes remains unclear, post-transplant obesity is a significant risk factor for graft failure Post print, cite as: Chan, W., Bosch, J.A., Jones, D., McTernan, P.G., Phillips, A.C., & Borrows, R. (2014). Obesity in kidney transplantation. Journal of Renal Nutrition, 24, 1-12. IF 1.57. http://dx.doi.org/10.1053/j.jrn.2013.09.002 and mortality. Obesity intervention post-transplantation focusing on nutritional therapy has shown encouraging results in weight management, but the impact on long term outcomes has not been demonstrated. There is now emerging data signifying the relevance and benefit of nutritional intervention in KTRs. It is therefore important that future research should focus on conducting nutritional intervention studies aiming to improve kidney transplant outcomes in this population group.
Practical application
This review article is the first to not only highlight the role of nutritional intervention and the impact of sarcopenia on kidney transplant outcomes, but to illustrate the complex pathophysiology of obesity in this patient population. Future research should focus on conducting prospective studies of nutritional intervention, aiming to evaluate the impact on outcomes of kidney transplantation.
